Activation of Platinum and Ruthenium Anticancer Prodrugs

  • ChemPubSoc Europe Logo
  • Author: Angewandte Chemie International Edition
  • Published Date: 21 March 2018
  • Source / Publisher: Angewandte Chemie International Edition/Wiley-VCH
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA
thumbnail image: Activation of Platinum and Ruthenium Anticancer Prodrugs

Platinum drugs are commonly used for the treatment of cancer. However, undesirable side effects are associated with their administration. Researchers have proposed a variety of solutions to overcome these problems, including the use of light-activatable prodrugs to localize the effects of anticancer agents.


Luca Salassa, Donostia International Physics Center, Donostia, and Ikerbasque, Basque Foundation for Science, Bilbao, both Spain, Fernando López-Gallego, CIC biomaGUNE, Donostia, and ARAID Foundation, Zaragoza, both Spain, and colleagues have developed a strategy for the light activation of metal-based anticancer prodrugs with high efficiency and selectivity. The researchers discovered that flavins, including some flavoproteins, can act as photosensitizers and photocatalysts to facilitate the transformation of platinum(IV) and ruthenium(II) complexes into bioactive species at convenient excitation wavelengths. Flavin catalysis towards metal complexes is bioorthogonal, meaning it occurs in the biological environment without interference from several biocomponents.


These results provide new design concepts in metal-based photochemotherapy, for instance, exploiting flavoproteins as endogenous phototriggers for prodrugs. Furthermore, the flavoenzyme NADH oxidase is capable of performing these unconventional reactions in the dark, hinting that flavoproteins may participate in the mechanism of action of platinum prodrugs.


 

Article Views: 1156

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

Bookmark and Share

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission. more


CONNECT:

ChemistryViews.org on Facebook

ChemistryViews.org on Twitter ChemistryViews.org on YouTube ChemistryViews.org on LinkedIn Sign up for our free newsletter


A product of ChemPubSoc Europe (16 European Chemical Societies)and Wiley-VCH